Search Results
Apr 03, 2026, 15:18 ET QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Apr 03, 2026, 13:30 ET GRANDEVITY Launches: Vitality and Energy for Adults Aged 50 to 100
appearance† Sleep patterns†"As a cardiologist, my passion is to design products that tap into the body's innate ability to favorably alter gene expression in support of healthy aging. Your genes do not need to define your destiny," says Mark R. Gordon, MD, FACC."I love simple, nature-inspired
More news about: GRANDEVITY
Apr 03, 2026, 07:32 ET Assembling Over 1,000 Human Genomes Affordably: New Method Powers Medicine's Future
scales (Fig. 2), including gene-altering SVs, pathogenic TR expansions, gene cluster variations, and HLA gene haplotypes. These findings indicate that the 1KCP variant catalog provides an important reference for the clinical screening of pathogenic mutations.By integrating gene expression data, the
More news about: Westlake University
Apr 02, 2026, 14:30 ET The University of Colorado Anschutz Gates Institute Achieves First-in-U.S. FDA Clearance for Campus-Built CAR T-Cell Therapy
cancers, where new treatment strategies are urgently needed."Fry agreed."This achievement highlights the strength of our growing cell and gene therapy ecosystem and the collaborative expertise required to advance a novel therapy from discovery to clinical testing," he said. "It's a powerful
More news about: University of Colorado Anschutz
Apr 02, 2026, 12:00 ET Greenland Mines Subsidiary Major Precious Greenland A/S Joins Greenland Business Association
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80%
More news about: Greenland Mines Ltd
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Apr 02, 2026, 09:00 ET BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
clinical and translational research development for BillionToOne's Northstar oncology portfolio. Northstar Select® is an ultra-sensitive, 84-gene, single-molecule NGS-based ctDNA panel designed to identify actionable genomic alterations in patients with advanced solid tumors, giving oncologists
More news about: BillionToOne
Apr 02, 2026, 08:40 ET Electric Innovation Initiative Opens Submissions for 2026 Electric Innovation Awards
CopperAdam Zurofsky, Advisor, Commonweal VenturesDylan McDowell, CEO, National Caucus of Environmental Legislators (NCEL)Gene Rodrigues, Former Assistant Secretary of Energy for Electricity and Energy Reliability, U.S. Department of EnergyEmily Warren, Deputy
More news about: Electric Innovation Initiative
Apr 02, 2026, 07:33 ET NUHS CHARTS NEW ERA OF PERSONALISED CARE WITH GENOMICS AND DATA-GUIDED BREAKTHROUGHS
genetic cause of diabetes due to a variant in the INS gene.When planning for a family in her late 20s, she returned for pre-conception family planning. Newer genomic technology confirmed that she did indeed carry a mutation in the INS gene which causes autosomal dominant INS‑related permanent
More news about: National University Health System (NUHS)
Apr 01, 2026, 15:59 ET Synthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents
fundamental gene-editing modifications, we hope to ensure that researchers and therapeutic developers can continue to innovate without the burden of invalid patent claims."The conclusion of this case comes at a pivotal time for Synthego as it continues to expand its leadership in the cell and gene therapy
More news about: Synthego
Apr 01, 2026, 14:24 ET QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Apr 01, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing
More news about: Levi & Korsinsky, LLP
Apr 01, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for April 2026
www.xtalks.com to see our upcoming webinars:CELL AND GENE THERAPYApr 28 - Accelerating Time to Data in Cell and Gene Therapy TrialsCLINICAL TRIALSApr 9 - Improve Recruitment Outcomes Through More Diverse Clinical
More news about: Xtalks
Apr 01, 2026, 08:00 ET Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
worldwide. In the U.S., nearly 2,500 people are diagnosed with IDH1-mutant gliomas each year, of which more than 95% harbor a mutation in the IDH1 gene. Most patients are diagnosed in their 30s and 40s. While patients with IDH1 mutations generally have longer survival times than those with wild-type IDH1,
More news about: Nuvation Bio Inc.
Apr 01, 2026, 06:30 ET Sino Biological ProPure™ Endotoxin-Free Proteins: The "Invisible Guardian" of Biopharmaceuticals
Minute quantities can provoke strong immune responses, compromise experimental accuracy, and threaten patient safety—especially in immunology, cell and gene therapy, and vaccine development. Endotoxin-free proteins are therefore critical for ensuring accuracy, safety, and regulatory compliance in sensitive
More news about: Sino Biological, Inc.
Mar 31, 2026, 20:49 ET The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
is developing prime editing — a next-generation gene editing platform that rewrites DNA without cutting both strands, reducing the off-target risks that have haunted earlier CRISPR approaches. The technology promises more precise manufacturing of gene-corrected cells at scale. Madrigal Pharmaceuticals
More news about: USA News Group
Mar 31, 2026, 19:00 ET NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and the United States, providing support across gene therapy, APIs, and both large‑ and small‑molecule manufacturing. The company offers a broad range of innovative platforms and capabilities—from preclinical
More news about: Ajinomoto Bio-Pharma Services
Mar 31, 2026, 19:00 ET NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and the United States, providing support across gene therapy, APIs, and both large‑ and small‑molecule manufacturing. The company offers a broad range of innovative platforms and capabilities—from preclinical
More news about: Ajinomoto Bio-Pharma Services
Mar 31, 2026, 12:00 ET NRGene Canada Launches MaxBites™ Premium Pet Treat, Entering the Fast-Growing North American Pet Nutrition Market
delivers products that maximize both animal health and resource efficiency – all achieved exclusively through natural genetics, without the use of GMO, gene editing, CRISPR, or any other artificial technologies.Logo:
More news about: NRGene
Mar 31, 2026, 12:00 ET NRGene Canada Launches MaxBites™ Premium Pet Treat, Entering the Fast-Growing North American Pet Nutrition Market
delivers products that maximize both animal health and resource efficiency – all achieved exclusively through natural genetics, without the use of GMO, gene editing, CRISPR, or any other artificial technologies.Logo:
More news about: NRGene
Mar 31, 2026, 11:32 ET Cell Therapy Market Size to Surpass USD 17.15 Billion by 2032, Driven by Chronic Disease Treatment and CAR-T Therapy Growth, Says New MMR Analysis
breakthroughs in CAR-T therapy, allogeneic cell therapies, and regenerative medicine. Rising prevalence of chronic and rare diseases and integration of gene-editing technologies like CRISPR-Cas9 are transforming treatment paradigms. Expanding cell therapy infrastructure and biobanking facilities across North
More news about: Maximize Market Research Pvt. Ltd.
Mar 31, 2026, 11:11 ET New FDA Plausible Mechanism Framework Spurs Development of Personalized In Vivo Prime Editing Platform for Urea Cycle Disorders
Gene Therapy for Inherited Metabolic Disorders Frontier Program and
More news about: Children's Hospital of Philadelphia
Mar 31, 2026, 11:00 ET Alltrna Announces Approval to Initiate First-in-Human Clinical Trial of AP003, the First tRNA Therapeutic to Enter Clinical Trials
in development for the treatment of patients with liver Stop Codon Disease that carry an arginine-to-TGA (Arg-TGA) nonsense mutation in the affected gene. The Arg-TGA variant occurs when a single base of the arginine-encoding codons, CGA and AGA, mutates to UGA (TGA in DNA), a termination codon for which
More news about: Alltrna
Mar 31, 2026, 09:00 ET RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm